Timothy Beukelman

List of Publications by Citations

110 papers	6,005 citations	39 h-index	76 g-index
134 ext. papers	7,080 ext. citations	5.1 avg, IF	5.39 L-index

#	Paper	IF	Citations
110	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care and Research*, **2012**, 64, 625-39	4.7	1199
109	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care and Research*, **2011**, 63, 465-82	4.7	531
108	Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA - Journal of the American Medical Association*, **2011**, 306, 2331-9	27.4	256
107	Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. *Journal of Rheumatology*, **2007**, 34, 1133-8	4.1	220
106	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis and Rheumatism*, **2013**, 65, 2499-512		177
105	Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. *JAMA - Journal of the American Medical Association*, **2013**, 309, 887-95	27.4	162
104	Geographic distribution of endemic fungal infections among older persons, United States. *Emerging Infectious Diseases*, **2011**, 17, 1664-9	10.2	134
103	Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis and Rheumatism*, **2012**, 64, 1263-71		129
102	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care and Research*, **2012**, 64, 1001-10	4.7	114
101	Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. *Arthritis and Rheumatology*, **2020**, 72, 326-334	9.5	114
100	Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. *Arthritis and Rheumatism*, **2012**, 64, 2773-80		113
99	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. *Arthritis and Rheumatology*, **2016**, 68, 56-66	9.5	101
98	Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). *Journal of Rheumatology*, **2008**, 35, 343-8	4.1	93
97	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. *JAMA Dermatology*, **2016**, 152, 164-72	5.1	88
96	Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. *Arthritis and Rheumatism*, **2013**, 65, 48-58		87
95	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. *Arthritis Care and Research*, **2019**, 71, 703-716	4.7	85
94	Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. *Arthritis Care and Research*, **2015**, 67, 731-6	4.7	82

93	Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. *Journal of Rheumatology*, **2012**, 39, 1880-7	4.1	80
92	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. *Annals of the Rheumatic Diseases*, **2014**, 73, 1942-8	2.4	77
91	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. *Annals of the Rheumatic Diseases*, **2011**, 70, 1401-6	2.4	77
90	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. *Arthritis Care and Research*, **2019**, 71, 717-734	4.7	76
89	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care and Research*, **2013**, 65, 1551-63	4.7	70
88	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. *Annals of the Rheumatic Diseases*, **2015**, 74, 1065-71	2.4	64
87	Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. *Journal of Rheumatology*, **2012**, 39, 1867-74	4.1	63
86	Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. *Journal of Oral and Maxillofacial Surgery*, **2012**, 70, 1802-7	1.8	63
85	Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. *Journal of Rheumatology*, **2012**, 39, 2341-51	4.1	59
84	Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. *Journal of Rheumatology*, **2011**, 38, 180-1	4.1	58
83	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. *Journal of Immunology*, **2016**, 196, 2492-503	5.3	58
82	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. *Arthritis and Rheumatology*, **2019**, 71, 846-863	9.5	54
81	Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura. *Journal of Pediatrics*, **2009**, 155, 136-9	3.6	54
80	Development and retrospective validation of the juvenile spondyloarthritis disease activity index. *Arthritis Care and Research*, **2014**, 66, 1775-82	4.7	49
79	Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. *American Journal of Ophthalmology*, **2013**, 155, 183-189.e1	4.9	46
78	High doses of infliximab in the management of juvenile idiopathic arthritis. *Journal of Rheumatology*, **2013**, 40, 1749-55	4.1	46
77	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. *Pediatric Rheumatology*, **2017**, 15, 30	3.5	43
76	Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2013**, 65, 1384-9		43

75	Attainment of inactive disease status following initiation of TNF-Inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. *Journal of Rheumatology*, **2011**, 38, 2675-81	4.1	43
74	Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. *Arthritis Care and Research*, **2011**, 63, 10-6	4.7	42
73	Imaging of the temporomandibular joint in juvenile idiopathic arthritis. *Arthritis Care and Research*, **2014**, 66, 47-54	4.7	41
72	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. *Arthritis and Rheumatology*, **2017**, 69, 1733-1740	9.5	40
71	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. *Arthritis Care and Research*, **2012**, 64, 1480-9	4.7	39
70	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. *Arthritis Care and Research*, **2019**, 71, 482-491	4.7	37
69	Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. *Pediatric Radiology*, **2007**, 37, 544-8	2.8	34
68	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. *Arthritis and Rheumatology*, **2019**, 71, 864-877	9.5	33
67	Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. *Journal of Rheumatology*, **2015**, 42, 541-6	4.1	33
66	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. *Annals of the Rheumatic Diseases*, **2018**, 77, 1012-1016	2.4	33
65	Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. *Journal of Rheumatology*, **2013**, 40, 936-42	4.1	30
64	The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. *Arthritis Research and Therapy*, **2016**, 18, 210	5.7	30
63	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. *Pediatric Rheumatology*, **2017**, 15, 23	3.5	28
62	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 1199-209	2.6	28
61	Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. *Arthritis Research and Therapy*, **2017**, 19, 84	5.7	27
60	Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?. *Pediatric Rheumatology*, **2010**, 8, 23	3.5	27
59	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. *Journal of Pediatrics*, **2017**, 184, 38-44.61	3.6	26
58	Treatment advances in systemic juvenile idiopathic arthritis. *F1000prime Reports*, **2014**, 6, 21		26

57	Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. *Arthritis Care and Research*, **2015**, 67, 624-32	4.7	25
56	Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. *Pediatric Rheumatology*, **2018**, 16, 71	3.5	24
55	Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al. *Arthritis Care and Research*, **2014**, 66, 1430-1	4.7	23
54	Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. *Arthritis and Rheumatism*, **2008**, 59, 1580-8		23
53	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. *Arthritis and Rheumatology*, **2019**, 71, 451-459	9.5	23
52	Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. *Journal of Rheumatology*, **2006**, 33, 2330-6	4.1	23
51	Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3302-7	5.6	22
50	What is the background incidence of malignancy in children with rheumatic disease?. *Current Rheumatology Reports*, **2013**, 15, 310	4.9	21
49	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. *Contemporary Clinical Trials*, **2012**, 33, 1211-6	2.3	21
48	Using registries to identify adverse events in rheumatic diseases. *Pediatrics*, **2013**, 132, e1384-94	7.4	21
47	Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. *Pediatric Clinics of North America*, **2018**, 65, 657-674	3.6	20
46	Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. *Pediatric Rheumatology*, **2013**, 11, 25	3.5	20
45	Infectious complications in juvenile idiopathic arthritis. *Current Rheumatology Reports*, **2013**, 15, 327	4.9	18
44	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. *Arthritis and Rheumatology*, **2018**, 70, 1508-1518	9.5	17
43	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. *Pediatric Rheumatology*, **2017**, 15, 31	3.5	17
42	Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. *Journal of Rheumatology*, **2007**, 34, 1918-24	4.1	17
41	Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. *Journal of Rheumatology*, **2017**, 44, 352-360	4.1	16
40	Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. *Arthritis and Rheumatism*, **2010**, 62, 2499-509		16

39	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2020**, 72, 1945-1951	9.5	15
38	Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. *Pediatric Rheumatology*, **2017**, 15, 52	3.5	14
37	Risk Factors for Intraarticular Heterotopic Bone Formation in the Temporomandibular Joint in Juvenile Idiopathic Arthritis. *Journal of Rheumatology*, **2018**, 45, 1301-1307	4.1	14
36	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). *Clinical Trials*, **2018**, 15, 268-277	2.2	13
35	Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. *Osteoporosis International*, **2010**, 21, 1573-84	5.3	13
34	Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis. *Journal of Rheumatology*, **2015**, 42, 2155-9	4.1	12
33	Risk of malignancy associated with biologic agents in pediatric rheumatic disease. *Current Opinion in Rheumatology*, **2014**, 26, 538-42	5.3	12
32	High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. *Pediatric Rheumatology*, **2011**, 9, 20	3.5	12
31	Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States.. *Journal of Scleroderma and Related Disorders*, **2018**, 3, 189-190	2.3	12
30	Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. *Journal of Rheumatology*, **2014**, 41, 2078-84	4.1	11
29	Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. *Journal of Rheumatology*, **2018**, 45, 107-114	4.1	9
28	Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2016**, 68, 1803-1811	4.7	9
27	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. *Pediatric Rheumatology*, **2016**, 14, 49	3.5	9
26	Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. *Pediatric Rheumatology*, **2019**, 17, 77	3.5	9
25	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. *Arthritis and Rheumatology*, **2018**, 70, 594-605	9.5	8
24	Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. *JAMA Internal Medicine*, **2018**, 178, 1224-1229	11.5	8
23	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. *Journal of Rheumatology*, **2017**, 44, 1884-1888	4.1	8
22	Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. *Arthritis Care and Research*, **2015**, 67, 529-37	4.7	7

21	Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility. *Pediatric Rheumatology*, **2012**, 10, 17	3.5	7
20	Temporomandibular joint arthritis in pediatric sjogren disease and sarcoidosis. *Journal of Rheumatology*, **2011**, 38, 2272-3	4.1	7
19	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. *Arthritis and Rheumatology*, **2021**, 73, 1898-1909	9.5	7
18	Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. *Pediatric Rheumatology*, **2017**, 15, 79	3.5	6
17	Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software. *Journal of Rheumatology*, **2007**, 34, 234; author reply 234-5	4.1	6
16	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2019**, 71, 1976-1984	9.5	5
15	Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. *Journal of Rheumatology*, **2014**, 41, 113-8	4.1	5
14	Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers. *Arthritis Care and Research*, **2021**, 73, 374-385	4.7	5
13	The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States.. *Journal of Scleroderma and Related Disorders*, **2019**, 4, 77-78	2.3	3
12	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. *Journal of Rheumatology*, **2021**, 48, 1322-1329	4.1	3
11	Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. *Arthritis Care and Research*, **2021**, 73, 940-946	4.7	3
10	Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children. *American Journal of Epidemiology*, **2021**, 190, 403-412	3.8	2
9	Trial Design, Measurement, and Analysis of Clinical Investigations **2016**, 54-77.e2		1
8	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. *Journal of Pediatrics*, **2017**, 189, 31-39	3.6	1
7	A20: Understanding the Use and Biology of TNF Therapy in JIA□linical Outcomes. *Arthritis and Rheumatology*, **2014**, 66, S31-S32	9.5	1
6	Juvenile idiopathic arthritis **2013**, 637-647		1
5	Primary Oral Presentation of Sarcoidosis in a Pediatric Patient. *Journal of Oral and Maxillofacial Surgery*, **2019**, 77, 1180-1186	1.8	1
4	Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. *Pediatric Rheumatology*, **2021**, 19, 131	3.5	1

3	Pharmacosurveillance in Juvenile Idiopathic Arthritis. *Rheumatic Disease Clinics of North America*, **2021**, 47, 643-653	2.4	1
2	Reply. *Arthritis and Rheumatology*, **2020**, 72, 1040-1041	9.5	
1	Juvenile Idiopathic Arthritis **2019**, 723-733.e1		